Introduction
The rationale for initiating long-term prophylaxis in von Willebrand disease (VWD) is two-fold. First, joint hemorrhages with development of arthropathy can occur, particularly in type 3 VWD, and frequent mucous membrane bleeds, gastrointestinal bleeding, and menorrhagia can jeopardize quality of life or even be life-threatening. Second, it has been successfully used in severe hemophilia, showing that it is feasible to implement early in life in a home setting, and that prevention of joint disease and other bleeds is possible [1, 2] . It is logical to consider application of the experience learned in hemophilia to VWD. Data to support long-term prophylaxis in VWD come from a few, less well-controlled cohort studies using retrospective designs [3, 4] .
The von Willebrand Disease Prophylaxis Network (VWD PN) is an international study group formed with the goal of evaluating prophylactic regimens for people with severe VWD. The VWD International Prophylaxis study (VIP) is an initiative of the VWD PN comprising a group of retrospective and prospective studies. In a recently published VIP retrospective study report, it was concluded that prophylactic treatment of VWD is efficacious [5] . This study was the largest so far comprising data from 59 patients enrolled in 20 centers from 10 countries. The number of patients with type 3 VWD was large (n ¼ 34; 57%) compared with other reports. The results showed significant overall reduction of hemorrhages for each indication examined.
In the above-referenced reports and in other studies of replacement therapy in VWD [6] , it is clear that prophylaxis is efficacious. However, the response of specific bleeding types has not been comprehensively studied. Combining data from the prospective and retrospective VIP studies provides a substantial number of bleeding events occurring prior to and during prophylaxis. The objective of the present study is to investigate the response to prophylaxis focusing primarily on epistaxis, joint bleeding, gastrointestinal bleeding, and heavy bleeding associated with menses (menorrhagia).
Methods

Subject population
Subjects enrolled in the prospective or retrospective VIP studies were included. Prophylaxis was defined as receiving factor infusions at least once per week to prevent or decrease the severity of bleeding with the intention of maintaining this regimen for 45 or more weeks per year, or receiving factor infusions on a regular basis during menstrual periods to prevent or decrease the severity of menorrhagia.
The prospective study evaluated the effect of prophylaxis in a treatment escalation study design. Subjects were required to meet criteria specific to type of VWD and demonstrate patterns of bleeding specific to one of the indications under study.
The following VWD-type criteria were used for the prospective study:
( Subjects were excluded from the prospective study if they had acquired von Willebrand syndrome, a history of inhibitors, were already on prophylaxis, or had a history of noncompliance.
Inclusion criteria for the retrospective study included:
(1) Currently on a prophylactic regimen for VWD that was initiated at least 6 months prior to enrolment -OR-(2) A history of use of prophylaxis, for a period of at least 6 months, which was discontinued because it was no longer required. (3) Availability of records to document, or reliably estimate, the type and frequency of bleeding episodes prior to, and after, the initiation of prophylaxis.
For subjects enrolled in the retrospective study, the primary indication for prophylaxis was defined as the bleeding symptom accounting for half or more of his bleeding episodes. Subjects were excluded from the retrospective if they had a history of noncompliance.
Data were collected between 2008 and 2013. The human-subjects committees of collaborating institutions approved the VIP study in a compliance with the guidelines of the Declaration of Helsinki. The VIP study is registered at www.ClinicalTrials.gov (NCT00557908).
Clinical data collection Sources of information included center records, diaries, and bleeding logs. Variables included subject demographics, VWD type, location, and frequency of bleeding prior to, and after, the initiation of prophylaxis. Bleeding log data including site, treatment type, and dose were available for a total of 1116 bleeding episodes collected in the retrospective study.
The retrospective study period was defined as beginning at least 12 months prior to initiation of the first prophylactic regimen and ending at enrolment or at the conclusion of prophylaxis. For those enrolled in the prospective study, it was 12 months prior to initiation of the first prophylactic regimen and 1 year following the onset of prophylaxis.
Statistical methods
Annualized bleeding rates were calculated for the periods prior to prophylaxis and during prophylaxis. Rates were calculated for the primary indication by multiplying the total annual number of bleeding episodes by the proportion that occurred at the primary indication site. Medians and interquartile ranges are used to describe bleeding rates. In addition, a 'paired' approach was used to calculate the percentage change in number of bleeding episodes within individuals by subtracting the number of bleeds that occurred before prophylaxis from the number of bleeds during prophylaxis, then dividing by the number of bleeds that occurred before prophylaxis. A paired Wilcoxon signed-rank test was used to compare the bleeding rate by primary indication. A general linear model was used to compare percentage change in bleeding rate by indication while controlling for VWD diagnosis.
Results
One hundred and five subjects, 10 enrolled in the prospective study and 95 in the retrospective study, were available for analysis. The mean age at start of prophylaxis was 26 years (range 1-81). There were similar proportions of adults (n ¼ 56; 53.3%, mean age 42.7, range 18.5-80.6) and children (n ¼ 49; 46.7%, mean age 7.8, range 1.0-17.9) in our study. A child was defined as any patient below 18 years at onset of prophylaxis, and an adult was any patient 18 years or older.
A description of the cohort can be found in Table 1 . Among adults, there were more women participating than men, and among children, there were more boys than girls. The majority of subjects were of European descent, with smaller proportions of participants of African descent, Hispanic, Asian, and other races or ethnicities. The most common VWD type was type 3 (51.4%), followed by type 2A (23.8%), and type 1 (12.4%).
Gastrointestinal bleeding was the most common reason for initiation of prophylaxis among adults (34%), followed by joint bleeding (20.8%). For children, the most frequent sites were epistaxis (43.2%) and joint bleeding (31.8%).
Change in annualized bleeding rates by indication Reductions in annualized bleeding rates before and during prophylaxis and percentage change for those with primary bleeding indications of epistaxis, gastrointestinal bleeding, joint bleeding, and menorrhagia (N ¼ 80) were calculated ( Table 2 ). The median reductions in bleeding, within individuals, were significant for epistaxis (P < 0.0001), gastrointestinal bleeding (P ¼ 0.0003), joint bleeding (P < 0.0001), and menorrhagia (P ¼ 0.008). The results from a model controlling for VWD type showed that overall, indication did not predict the percentage change in bleed rates after onset of prophylaxis (P ¼ 0.12). However, the difference in percentage change between gastrointestinal bleeding and menorrhagia was significant (P ¼ 0.02) as well as the difference in percentage change between gastrointestinal bleeding and joint bleeding (P ¼ 0.04). Figure 1 displays the contribution of each of the major sites to the annualized bleeding rate prior to and during prophylaxis. Although the overall bleeding rate is much lower during prophylaxis in each VWD type, the contribution of each site to the total does not vary greatly, perhaps with the exception of type 1, compared with that observed in the period before prophylaxis. The greatest decrease in overall bleeding rate occurred among those with type 3 VWD.
Dose by bleeding type prior to and during prophylaxis and average dose by regimen All data reported in the retrospective study bleeding logs prior to and during prophylaxis were examined (Table 3) . Data from the prospective study were not used in this analysis because dose and frequency were specified by the protocol.
Focusing on the treatment for epistaxis, gastrointestinal bleeding, joint bleeding, and menorrhagia, dose was calculated by averaging across all the doses for the specific bleed type (Table 4) . There is not a notable difference in the mean doses given prior to the onset of prophylaxis for the treatment of episodic bleeding events and those given during prophylaxis. Prophylactic regimen was divided into two categories: those receiving prophylaxis less than three times per week/per cycle and those
Effect of prophylaxis by bleeding site in VWD Holm et al. 385 with an infusion frequency of three or more times per week/per cycle. The latter group generally had higher doses than those who received prophylaxis less frequently. This observation was strongest for joint bleeding. Data that would permit calculation of total product usage prior to and during prophylaxis were not collected as part of this study.
Discussion
It has been shown that long-term prophylaxis with VWFcontaining concentrates in cases of VWD is useful and capable of preventing recurrent bleeding and arthropathy, thereby improving quality of life. It is likely that health economic benefits will occur as a result of prophylaxis for VWD.
Severe VWD is a rare disease, and an international collaboration such as the VIP study makes it possible to answer a number of questions and develop guidelines for treatment and follow-up of those most severely Annualized rates of bleeding for the total study group and by von Willebrand disease (VWD) type are shown prior to and during prophylaxis in the stacked bars. Frequency distributions of bleeding by site prior to and during prophylaxis are shown in the columns that appear under the corresponding stacked bar. The category of 'Other' contains bleeding sites that occurred with low frequency. These include, for example, intracranial haemorrhage, hematomas in soft tissue, oral, dental extraction, scraped knees, ovarian cysts or bleeding. The percentages in each column sum to 100%. affected by the disease. Abshire et al. [5] showed that prophylactic treatment of VWD is effective in reducing bleeding and the current analysis extends that work to examine more closely the outcomes of specific bleeding types.
Data collected as part of the VIP retrospective and prospective studies were used. There were similar findings among adults and children participating, showing that the need for treatment was present across the age groups. Type 3 was the most common VWD-type in both age groups -approximately half of the total -followed by type 2. The high proportion of patients with type 3 is expected, given that the inclusion criteria required need for treatment with VWF concentrates.
The figure showed that the median annualized bleeding rate for the total study group and for each type was 12 -one bleeding episode per month. This is likely a reflection of the fact that participants in this study, regardless of VWD diagnosis, exhibited a frequency of bleeding that indicated a need for prophylaxis, confirming observations from cohort and registry studies that a subset of people with VWD experiences a significant degree of bleedingrelated morbidity. It may also be because of, to some degree, a form of digit preference related to the way data were collected. If a complete log of every bleeding episode for the year prior to prophylaxis was not available, investigators made an assessment of all available documentation to determine 'on average, how many episodes of bleeding occurred each month.'
The most frequent indication for starting prophylaxis for adults was gastrointestinal bleeding and the lowest response in terms of reduction of bleeding events occurred among this group. Gastrointestinal bleeding occurred primarily among those with VWD type 2. This fits well with previous studies reporting angiodysplasia as a cause of gastrointestinal bleeding together with the coagulation defect. Angiodysplasia is reported to be more frequent in VWD compared with that seen in normal controls and especially frequent in type 2 and type 3 VWD wherein the function and level of VWF are more greatly impaired than in type 1. This lends credence to the speculation by Randi et al. and Franchini and Mannucci [7, 8] that VWF has antiangiogenic properties.
Doses on a group level were approximately the same prior to and during prophylaxis, but more patients with gastrointestinal bleeding had prophylaxis three or more times per week with a higher dosage each time. Clearly, new approaches for treating gastrointestinal bleeding are needed.
Epistaxis was the most common treatment indication for children. The proportional contribution of this indication was similar prior to and during prophylaxis. Treatment doses were also similar prior to and during prophylaxis and higher when patients were receiving three or more infusions per week. Dose escalation and more treatment occasions may be necessary to reach an optimal reduction of episodes of epistaxis.
Joint bleeding was represented equally in adults and children, mostly occurring among those with type 3 VWD. Treatment doses were higher during prophylaxis, particularly so among patients treated three or more times per week. Those with type 3 VWD and joint bleeding had the best response to prophylaxis, possibly because of the higher dosage.
Conclusion
This is by far the largest study presented in which the treatment and replacement effect of VWF-containing concentrates in VWD not responding to desmopressin are described. Institution of regular replacement therapy has a dramatic effect on bleeding frequency but does not change the proportions of type of bleeds that occur to a great extent. There is variation among patients with regard to response to therapy, both among and within subtypes of VWD. Gastrointestinal bleeding stands out, having a lower response to prophylaxis than other bleeding sites. Gastrointestinal bleeds appear to require more frequent prophylactic infusions. It was also noted that when the treatment frequency is escalated for joint bleeding, higher doses were used. Our study, mainly using retrospective data, indicates that prospective studies are needed to better delineate the doses and dose intervals that should be used for prophylactic treatment of VWD. It is likely that more tailored dosing can be used than seen in the present study in which doses were generally similar for all subtypes and indications. This is imperative from a health economic point of view.
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Further health economic analyses of cost per avoided bleed are necessary and relevant. It should also be borne in mind that different brands of VWF concentrates may require different dosing schedules, as their content of FVIII and VWF vary.
